SEC Comment Letter 0000000000-23-014201 to Sonnet BioTherapeutics Holdings, Inc. (SONN) (CIK 0001106838)

Sonnet BioTherapeutics Holdings, Inc. (SONN) (CIK 0001106838)
Date: Dec. 29, 2023 · CIK: 0001106838 · Accession: 0000000000-23-014201

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-276250

Date

December 29, 2023

Author

Not clearly detected

Form

UPLOAD

Company

Sonnet BioTherapeutics Holdings, Inc. (SONN) (CIK 0001106838)

Letter

United States securities and exchange commission logo December 29, 2023 Pankaj Mohan, Ph.D. CEO and Chairman Sonnet BioTherapeutics Holdings, Inc. 100 Overlook Center, Suite 102 Princeton, New Jersey 08540 Re:Sonnet BioTherapeutics Holdings, Inc. Registration Statement on Form S-3 Filed December 22, 2023 File No. 333-276250 Dear Pankaj Mohan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven M. Skolnick, Esq.

Show Raw Text

United States securities and exchange commission logo
December 29, 2023
Pankaj Mohan, Ph.D.
CEO and Chairman
Sonnet BioTherapeutics Holdings, Inc.
100 Overlook Center, Suite 102
Princeton, New Jersey 08540
Re:Sonnet BioTherapeutics Holdings, Inc.
Registration Statement on Form S-3
Filed December 22, 2023
File No. 333-276250
Dear Pankaj Mohan:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Steven M. Skolnick, Esq.

SecProbe.io